Home > Insider Trading > Filing (0000902664-23-004790)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267602	Alimera Sciences Inc	ALIM	Pharmaceutical Preparations (2834)	200028718

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1727492	Caligan Partners Lp	515 Madison Avenue 8Th Floor New York NY 10022		No	No	Yes	No
1785557	Edward David Johnson	590 Madison Avenue New York NY 10022		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value 0.01 Per Share (Common Stock)	Disposition	2023-09-14	579,000	$3.39	16,256,154	No	4	S	Indirect	See footnote
Common Stock	Acquisiton	2023-09-14	579,000	$3.39	16,835,154	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Notional Derivative Agreements (obligation to buy)	Acquisiton	2023-09-14	1	$0.00	490,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
490,000			Yes	4	J	Indirect

Footnotes

This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
Represents rebalancing transaction between the Caligan Fund and Accounts.
At the market close on September 14, 2023, the expiration date of the notional principal amount derivative agreements in the form of cash settled swaps previously reported on the Form 3 filed by the Reporting Persons on August 11, 2023, was extended from February 2, 2024 to September 26, 2025.